Lighter You Review: $169 Advertised, $339 Charged

Lighter You (lighteryou.co) advertises tirzepatide "starting at $169/mo" on its marketing site. Its own store charges $339 for four weeks of it. Both were live on 1 September 2026, on the same brand, on the same day — and the same gap, in the same direction, runs through almost every product it sells.

This is a rewrite. In August we could not price this company at all: the whole public price surface was seven marketing strings and every button led to an account gate. That has changed, and the change is genuinely an improvement — the store now publishes a figure per product, per dose, before any intake. What it also did was make the disagreement visible.

What is advertised, and what is charged

| product | marketing site | store and intake | |---|---|---| | semaglutide injection | starting at $169/mo | $169 per 4 weeks | | tirzepatide injection | starting at $169/mo | **$339 per 4 weeks** | | oral semaglutide tablet | starting at $249 | $279 per 4 weeks | | low-dose injections (six products) | starting at $96 | $179 per 4 weeks, every one |

Semaglutide is the one figure that matches. Tirzepatide is exactly double what is advertised. The low-dose line is advertised at a number no product in it costs, and the advertised figure is $83 below the real one on every single item.¹

A fourth price list exists on a peptide sub-brand run by the same company, and it prices the shared side products differently again. So a shopper can meet three different numbers for the same item without leaving the operator.

"/mo" is four weeks

The marketing site writes "/mo". The store writes "per 4 week". Four-week billing comes round thirteen times a year, not twelve — so even the semaglutide figure that does match is about $2,197 a year rather than $2,028, and tirzepatide is about $4,407 rather than $4,068. The teaser-rate trap covers why a cadence stated in one place and implied differently in another is worth as much attention as the number itself.

What the gap means for a price ranking

A row can be ranked on a figure it publishes. Lighter You now publishes one, so it is on the semaglutide price ladder at its store price rather than its advertised one — $169 per four weeks, which is the figure a buyer is actually charged. The tirzepatide column carries $339 for the same reason, and says so.

That is the general rule this desk follows and it is worth stating plainly: when a seller's marketing and its checkout disagree, the checkout is the price and the marketing is a finding.

What it is, though — because it is not a shell

Lighter You names **three pharmacies, with street addresses and phone numbers**: RedRock Pharmacy in St. George, Utah; Health Warehouse in Florence, Kentucky; and Precision Compounding Pharmacy. That is better supply-chain disclosure than most of the market manages, and considerably better than the sellers that name none. Its intake consent names OpenLoop Health as the clinical layer, and its legal pages are complete rather than boilerplate.

It also displays a certification badge. We report that it displays one and stop there — a badge image that loads proves the seal number was issued, not who holds it, and this site does not treat that as verification of anything.

So the problem here is not that nobody is home. It is that a company doing the checkable parts properly is advertising a price it does not charge.

The contradictions

The terms say services are offered "in all 50 states plus Washington D.C.". The footer, on every page of the same site, says "Not available in all 50 states." Both sentences are live, and no exclusion list is published.

The questions promise a month-to-month membership with a 30-day satisfaction guarantee. The refund policy contradicts it in block capitals: in no event shall a refund be issued on cancellation. Cancellation requires 72 hours' notice before the billing date, and the effect lands on the cycle after that.

And you are charged when you complete the intake, before a provider reviews it. Combine that with the refund clause and the practical position is that your first payment is at risk from the moment you submit.

A badge on the homepage says purchases are eligible for a tax-advantaged health account. The terms decline to guarantee that any amount paid is eligible for reimbursement by insurance or by such an account.

Who is prescribing

Nobody is named. No clinician, no medical group, no identifier, and no statement of which of the three named pharmacies fills a given order. Lighter You, LLC publishes no address. How to verify a compounding pharmacy is legitimate is the check you can partly run here, because the pharmacies have names; the prescriber half of it, you cannot run at all.

The regulatory screen

The trading name and the named pharmacies returned zero company-column matches in the FDA's live warning-letter index, as did the clinical partner.² The pass carried a positive control — a real letter to an unrelated seller — which returned correctly, so the zeros are evidence rather than a query that quietly failed.

One thing to be careful about, because it is an easy misattribution: searching the phrase "lighter you" does return a February 2026 letter, but it belongs to a tobacco company operating a similarly named domain. It is not this business, and nothing about it should be read onto this one.

The verdict for a bargain hunter

Semaglutide at $169 for four weeks is a fair mid-field price and the advertised figure is honest on that one product. Everything else on the shelf costs more than the page that sold it to you said. Budget thirteen charges a year, price the product you actually want in the store rather than on the marketing site, and read how to choose a GLP-1 provider without overpaying before you submit an intake that charges your card. The rest of what we publish is in the research library.